Company profile
bioAffinity Technologies, Inc.
NASDAQ: BIAF · Healthcare · Medical - Diagnostics & Research
#688 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
32DFH 38DQ 16GM 41SS 40
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, balance-sheet leverage · ↓ growth stability, filing timeliness
Methodology →Revenue TTM
$5.7M
Rev growth YoY (TTM)
-35.8%
Net income (FY)
-$14.9M
Employees
57
as of 2026-08-24
Market cap
$37.7M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$6.2M$6.2M2025
Net income-$14.9M-$14.9M2025
Operating income-$10.6M-$10.6M2025
Total assets$11.0M$11.0M2025
Liabilities$3.7M$3.7M2025
Equity$7.3M$7.3M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Health Care, Patient Service100%
Other Revenues0%
By geography
Not disclosed.
The read
What is bioAffinity Technologies, Inc.’s revenue?
bioAffinity Technologies, Inc. booked $6.2M in FY2025 revenue, contracting 34% year over year — slower than 77% of Healthcare companies we track, at a -242.0% net margin.
Peers · Healthcare
Jack Nathan Medical Corp.——Scorpius Holdings, Inc.——Decision Diagnostics Corp.——Oracle Healthcare Acquisition Corp.——Bloomios, Inc.——Australis Capital Inc.——Neighbors
Bexar →Key facts
CEOMaria Zannes
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersSan Antonio, TX
ExchangeNASDAQ: BIAF
Employees57
IPO date2022-09-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.